FDA Approves Medicines360's sNDA for LILETTA(R) (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Five Years

DUBLIN and SAN FRANCISCO, Oct. 16, 2018 -- (Healthcare Sales & Marketing Network) -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Medicines360, a global nonprofit women's health pharmaceutical company with a mission of expanding ... Biopharmaceuticals, Drug Delivery, FDA Medicines360, Allergan, LILETTA, levonorgestrel, contraceptive
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news